You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder
SBC: PHOENIX PHARMALABS, INC. Topic: NIDAAbstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NHLBISummary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Closed-loop laryngeal pacing for voice restoration
SBC: RIPPLE LLC Topic: NIDCDProject Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters
SBC: NYTRICX INC Topic: NHLBIAbstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
SBC: MOONLIGHT THERAPEUTICS, INC. Topic: NIAIDThe following contains proprietary/privileged information that Moonlight Therapeutics requests not be released to persons outside the government, except for purposes of review and evaluation Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within theSkin) patch for the Treatment of Peanut Allergy Food allergies affect 30 million people in the USA and 17 million in ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Expansion and validation of novel mobile app for guiding home modifications for aging in place
SBC: HomesRenewed Ventures LLC Topic: RPROJECT SUMMARY In this Phase II SBIR, HomesRenewed Ventures, LLC (HRV Washington, DC) will build on our previous efforts to expand and validate an interactive mobile application (APP) for guiding home modifications (environmental interventions) critical to Aging in Place (AiP). Home modifications (HM) are associated with falls preventions, improved activities of daily living (ADLs), and emotional ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
High-throughput functional analysis and clinical relevance of all possible variants of a gene
SBC: HELIGENICS, INC. Topic: NHGRIModern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities
SBC: WI-SENSE LLC Topic: NHLBIProject Abstract Asthma affects 25 million Americans, and chronic obstructive pulmonary disease (COPD) affects 16 million,together costing 130 billion USD annually to the US healthcare system. Asthma is more prevalent in AfricanAmerican population (10.6%) than white population (7.7%). Poverty level has an impact as well, with twice asmuch asthma incidence in people below 100% of the poverty thresh ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health